Galafold
Payments companies reported to CMS as associated with Galafold. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Galafold, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Galafold
These are the largest totals companies reported as associated with Galafold. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Robert Hopkin | Cincinnati, OH | Clinical Genetics (M.D.) | $61,520.92 |
| Staci Kallish | Philadelphia, PA | Clinical Genetics (M.D.) | $50,948.54 |
| John Jefferies | Memphis, TN | Advanced Heart Failure and Transplant Cardiology | $19,118.25 |
| Cecilia Ortiz | San Antonio, TX | Gerontology (Nurse Practitioner) | $12,611.10 |
| Usman Tahir | Boston, MA | Cardiovascular Disease | $12,565.00 |
| Damara Ortiz | Pittsburgh, PA | Clinical Genetics (M.D.) | $11,774.56 |
| Priya Kishnani | Durham, NC | Pediatrics | $11,529.85 |
| Zurisadai Gonzalez Castillo | Dallas, TX | Neurology With Special Qualifications In Child Neurology | $11,266.56 |
| Martin Maron | Burlington, MA | Cardiovascular Disease | $9,004.00 |
| Anjay Rastogi | Los Angeles, CA | Nephrology (Internal Medicine) | $6,550.92 |
Prescribed Galafold?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.